Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Net Income towards Common Stockholders: 2014-2024

Historic Net Income towards Common Stockholders for Collegium Pharmaceutical (COLL) over the last 11 years, with Dec 2024 value amounting to $42.4 million.

  • Collegium Pharmaceutical's Net Income towards Common Stockholders rose 237.51% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.4 million, marking a year-over-year decrease of 34.03%. This contributed to the annual value of $42.4 million for FY2024, which is 7.88% down from last year.
  • According to the latest figures from FY2024, Collegium Pharmaceutical's Net Income towards Common Stockholders is $42.4 million, which was down 7.88% from $46.0 million recorded in FY2023.
  • Collegium Pharmaceutical's Net Income towards Common Stockholders' 5-year high stood at $71.5 million during FY2021, with a 5-year trough of -$33.6 million in FY2022.
  • Its 3-year average for Net Income towards Common Stockholders is $18.3 million, with a median of $42.4 million in 2024.
  • Per our database at Business Quant, Collegium Pharmaceutical's Net Income towards Common Stockholders crashed by 146.92% in 2022 and then surged by 237.10% in 2023.
  • Yearly analysis of 5 years shows Collegium Pharmaceutical's Net Income towards Common Stockholders stood at $26.8 million in 2020, then soared by 167.33% to $71.5 million in 2021, then tumbled by 146.92% to -$33.6 million in 2022, then skyrocketed by 237.10% to $46.0 million in 2023, then dropped by 7.88% to $42.4 million in 2024.